Zivanovic Oliver, Sonoda Yukio, Diaz John P, Levine Douglas A, Brown Carol L, Chi Dennis S, Barakat Richard R, Abu-Rustum Nadeem R
Department of Surgery, Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Gynecol Oncol. 2008 Dec;111(3):431-7. doi: 10.1016/j.ygyno.2008.08.024. Epub 2008 Oct 16.
The aim was to describe the rate of laparoscopic trocar-related subcutaneous tumor implants in women with underlying malignant disease.
An analysis of a prospective database of all patients undergoing transperitoneal laparoscopic procedures for malignant conditions performed by the gynecologic oncology service.
Between July 1991 and April 2007, laparoscopic procedures were performed in 1694 patients with a malignant intraabdominal condition and in 505 breast cancer patients undergoing risk-reducing, diagnostic or therapeutic laparoscopic procedures without intraabdominal disease. Port-site metastases were documented in 20 of 1694 patients (1.18%) who underwent laparoscopic procedures for a malignant intraabdominal condition. Of these, 15 patients had a diagnosis of epithelial ovarian or fallopian tube carcinoma, 2 had breast cancer, 2 had cervical cancer, and 1 had uterine cancer. Nineteen of 20 patients (95%) had simultaneous carcinomatosis or metastases to other sites at the time of port-site metastasis. Patients who developed port-site metastases within 7 months from the laparoscopic procedure had a median survival of 12 months whereas patients who developed port-site metastasis >7 months had a median survival of 37 months (P=0.004). No port-site recurrence was documented in patients undergoing risk-reducing, diagnostic or therapeutic laparoscopic procedures for breast cancer without intraabdominal disease.
The rate of port-site tumor implantation after laparoscopic procedures in women with malignant disease is low and almost always occurs in the setting of synchronous, advanced intraabdominal or distant metastatic disease. The presence of port-site implantation is a surrogate for advanced disease and should not be used as an argument against laparoscopic surgery in gynecologic malignancies.
目的是描述患有潜在恶性疾病的女性腹腔镜套管针相关皮下肿瘤种植的发生率。
对妇科肿瘤服务部门为恶性疾病进行经腹腹腔镜手术的所有患者的前瞻性数据库进行分析。
在1991年7月至2007年4月期间,对1694例患有腹腔内恶性疾病的患者以及505例接受降低风险、诊断性或治疗性腹腔镜手术且无腹腔内疾病的乳腺癌患者进行了腹腔镜手术。在1694例接受腹腔镜手术治疗腹腔内恶性疾病的患者中,有20例(1.18%)记录有穿刺孔转移。其中,15例诊断为上皮性卵巢癌或输卵管癌,2例为乳腺癌,2例为宫颈癌,1例为子宫癌。20例患者中有19例(95%)在穿刺孔转移时同时伴有癌性腹膜炎或其他部位转移。腹腔镜手术后7个月内发生穿刺孔转移的患者中位生存期为12个月,而在7个月后发生穿刺孔转移的患者中位生存期为37个月(P = 0.004)。在接受降低风险、诊断性或治疗性腹腔镜手术且无腹腔内疾病的乳腺癌患者中,未记录有穿刺孔复发。
患有恶性疾病的女性腹腔镜手术后穿刺孔肿瘤种植的发生率较低,且几乎总是发生在同时存在晚期腹腔内或远处转移性疾病的情况下。穿刺孔种植的存在是晚期疾病的一个替代指标,不应作为反对妇科恶性肿瘤腹腔镜手术的理由。